Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial.

The common tumor-related symptoms were pain, fatigue and anorexia, from which 31.7, 22.2 and 14.8% of the patients suffered at baseline, but the proportions decreased to 8.6, 5.9 and 3.7%, respectively, at 24 weeks after the treatment in a time-dependent manner with a decreasing trend ( P < 0.0001).

also in 47,180 other papers